Literature DB >> 14984358

Osteoporosis: underrated, underdiagnosed and undertreated.

Tuan V Nguyen1, Jacqueline R Center, John A Eisman.   

Abstract

Osteoporosis is: (1) Underrated. Currently costs about 7 billion dollars annually in Australia. Has high morbidity and 2-3-fold increase in risk of death after any major osteoporotic fracture. Genetic factors contribute highly to risk, modified by lifestyle and hormonal factors. (2) Underdiagnosed. Bone density is a good predictor of subsequent risk. Anyone with a low-trauma fracture has osteoporosis unless proven otherwise. Every individual with a low trauma fracture should be investigated for exclusion of underlying osteoporosis and considered for effective treatment to reduce future fracture risk. More than 75% of women and about 90% of men with a high likelihood of osteoporosis are not investigated. (3) Undertreated. More than 75% of those affected are not treated. Effective treatments (eg, hormone replacement therapy, selective oestrogen receptor modifiers and bisphosphonates) reduce fracture risk by 30%-60%. Simple measures like vitamin D and calcium supplementation and use of hip protectors can reduce hip fractures, particularly in institutionalised and housebound elderly people

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984358     DOI: 10.5694/j.1326-5377.2004.tb05908.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  44 in total

Review 1.  Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments.

Authors:  Charles A Inderjeeth; Kien Chan; Kevin Kwan; Michelle Lai
Journal:  J Bone Miner Metab       Date:  2012-05-29       Impact factor: 2.626

2.  Effects of Lemon Beverage Containing Citric Acid with Calcium Supplementation on Bone Metabolism and Mineral Density in Postmenopausal Women: Double-Blind 11-Month Intervention Study.

Authors:  Hiromi Ikeda; Tadayuki Iida; Masanori Hiramitsu; Takashi Inoue; Satomi Aoi; Miho Kanazashi; Fumiko Ishizaki; Toshihide Harada
Journal:  J Nutr Metab       Date:  2021-02-24

3.  A team approach: implementing a model of care for preventing osteoporosis related fractures.

Authors:  M Giles; J Van Der Kallen; V Parker; K Cooper; K Gill; L Ross; S McNeill
Journal:  Osteoporos Int       Date:  2010-11-03       Impact factor: 4.507

Review 4.  Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density.

Authors:  S Nayak; D L Edwards; A A Saleh; S L Greenspan
Journal:  Osteoporos Int       Date:  2015-02-03       Impact factor: 4.507

5.  Barriers to secondary fracture prevention in primary care.

Authors:  A S Mendis; K Ganda; M J Seibel
Journal:  Osteoporos Int       Date:  2017-06-29       Impact factor: 4.507

Review 6.  The association between critical illness and changes in bone turnover in adults: a systematic review.

Authors:  N Orford; C Cattigan; S L Brennan; M Kotowicz; J Pasco; D J Cooper
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

7.  Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.

Authors:  J D Ringe; H Faber; P Farahmand; A Dorst
Journal:  Rheumatol Int       Date:  2005-07-07       Impact factor: 2.631

8.  Effect of IV contrast on lumbar trabecular attenuation at routine abdominal CT: correlation with DXA and implications for opportunistic osteoporosis screening.

Authors:  P J Pickhardt; T Lauder; B D Pooler; A Muñoz Del Rio; H Rosas; R J Bruce; N Binkley
Journal:  Osteoporos Int       Date:  2015-07-08       Impact factor: 4.507

9.  Management of osteoporosis in central and eastern Europe (CEE): conclusions of the "2nd Summit on Osteoporosis-CEE", 21-22 November 2008, Warsaw, Poland.

Authors:  Roman S Lorenc; Heinrich Resch
Journal:  Arch Osteoporos       Date:  2009-09-18       Impact factor: 2.617

10.  Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.

Authors:  E Michael Lewiecki
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.